Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
Tsetsegsaikhan Batmunkh, Marguerite T. Dalmau, Margad-Erdene Munkhsaikhan, et al.
Vaccine (2020) Vol. 38, Iss. 27, pp. 4316-4324
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Human Papillomavirus Vaccination After COVID-19
Zheng Quan Toh, Fiona M. Russell, Suzanne M. Garland, et al.
JNCI Cancer Spectrum (2021) Vol. 5, Iss. 2
Open Access | Times Cited: 57
Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs
Lauri E. Markowitz, Mélanie Drolet, Rayleen M. Lewis, et al.
Vaccine (2022) Vol. 40, Iss. 37, pp. 5413-5432
Open Access | Times Cited: 29
Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?
Chau Quang, Amy W. Chung, Ian H. Frazer, et al.
Trends in Immunology (2022) Vol. 43, Iss. 10, pp. 815-825
Closed Access | Times Cited: 19
Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9–14 years: A randomized and open-label clinical trial
Fangqin Xie, Kevin Du, Junrong Li, et al.
Vaccine (2025) Vol. 55, pp. 127015-127015
Open Access
Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before–after design
Dorothy A. Machalek, Helen Rees, Admire Chikandiwa, et al.
BMJ Open (2022) Vol. 12, Iss. 2, pp. e059968-e059968
Open Access | Times Cited: 15
A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji
Rita Reyburn, Evelyn Tuivaga, Tupou Ratu, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 37, pp. 100798-100798
Open Access | Times Cited: 7
Evidence for an HPV one-dose schedule
Margaret Stanley, Anne Schuind, Kirthini Muralidharan, et al.
Vaccine (2024) Vol. 42, pp. S16-S21
Open Access | Times Cited: 2
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom
Vincent Daniels, Kunal Saxena, Oscar Patterson‐Lomba, et al.
Vaccine (2022) Vol. 40, Iss. 14, pp. 2173-2183
Open Access | Times Cited: 11
Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?
Barbara J. Kuter, Suzanne M. Garland, Anna R. Giuliano, et al.
Preventive Medicine (2021) Vol. 144, pp. 106321-106321
Closed Access | Times Cited: 14
Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study
Anna Loenenbach, Viktoria Schönfeld, Anja Takla, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 4
Unraveling Immunological Dynamics: HPV Infection in Women—Insights from Pregnancy
Carmen Elena Condrat, Dragoș Crețoiu, Viorica Rădoi, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 2011-2011
Open Access | Times Cited: 4
Moving towards a strategy to accelerate cervical cancer elimination in a high-burden city—Lessons learned from the Amazon city of Manaus, Brazil
Kátia Luz Torres, Heidy Halanna de Melo Farah Rondon, Toni Ricardo Martins, et al.
PLoS ONE (2021) Vol. 16, Iss. 10, pp. e0258539-e0258539
Open Access | Times Cited: 7
Single-Dose Human Papillomavirus Vaccination in Low- and Middle-Income Countries—Time for Implementation?
Delphine Gallant, Philippe Tummers, Steven Weyers, et al.
Journal of Pediatric and Adolescent Gynecology (2021) Vol. 34, Iss. 5, pp. 586-590
Closed Access | Times Cited: 6
Acceptance of Self-Sampling and Knowledge about Human Papillomavirus among Women in Mongolia
Tsetsegsaikhan Batmunkh, Unursaikhan Surenjav, Narantuya Namjil, et al.
Asian Pacific Journal of Cancer Prevention (2024) Vol. 25, Iss. 5, pp. 1823-1829
Open Access
Efficacité potentielle, efficacité réelle et immunogénicité des calendriers réduits de vaccination contre le VPH : examen des données probantes disponibles
Joshua Montroy, Marina I. Salvadori, Nicole Forbes, et al.
Relevé des maladies transmissibles au Canada (2024) Vol. 50, Iss. 6, pp. 183-196
Open Access
Efficacy, effectiveness and immunogenicity of reduced HPV vaccination schedules: A review of available evidence
Joshua Montroy, Marina I. Salvadori, Nicole Forbes, et al.
Canada Communicable Disease Report (2024) Vol. 50, Iss. 6, pp. 166-178
Open Access
The Clinical Effectiveness of Single-Dose Human Papillomavirus Vaccination
Wanying Bao, Xinlin He, Yue Huang, et al.
Vaccines (2024) Vol. 12, Iss. 9, pp. 956-956
Open Access
Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies
Ximing Hu, Yueling Chen, W.J. Lin, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 9
Closed Access
Community intervention of a single-dose or 2-dose regimen of bivalent human papillomavirus vaccine in schoolgirls in Thailand: vaccine effectiveness 2 years and 4 years after vaccination
Suchada Jiamsiri, Chulwoo Rhee, Hyeon Seon Ahn, et al.
JNCI Monographs (2024) Vol. 2024, Iss. 67, pp. 346-357
Open Access
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia
Vincent Daniels, Kunal Saxena, Oscar Patterson‐Lomba, et al.
PLoS ONE (2024) Vol. 19, Iss. 11, pp. e0310591-e0310591
Open Access
Quince años de vacunación frente al virus del papiloma humano en España. Actualización
F.A. Moraga Llop
Vacunas (2023) Vol. 24, Iss. 4, pp. 394-399
Closed Access | Times Cited: 1
The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study
Kosuke Hiramatsu, Yutaka Ueda, Asami Yagi, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 3
A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States
Michael G. Bruce, Elissa Meites, Lisa Bulkow, et al.
Vaccine (2020) Vol. 38, Iss. 42, pp. 6585-6591
Closed Access | Times Cited: 1
Australia’s Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific
Zheng Quan Toh, Chau Quang, Joseph A. Tooma, et al.
Vaccines (2021) Vol. 9, Iss. 8, pp. 921-921
Open Access | Times Cited: 1
Human papillomavirus infection associated with cervical cancer and other malignancies
Dirce Sakauchi, Aurora M. Cianciarullo
GSC Biological and Pharmaceutical Sciences (2023) Vol. 25, Iss. 1, pp. 164-177
Open Access
Page 1 - Next Page

Scroll to top